Immunotherapy in NSCLC With Concomitant KRAS/TP53 Mutations

EP: 1.Overview of Actionable Mutations and Molecular Profiling in NSCLC

EP: 2.Optimizing the Use of Molecular Profiling in Non–Small Cell Lung Cancer

EP: 3.Is There a Role for IO Therapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements?

EP: 4.Poor Outcomes With IO Therapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

EP: 5.IO Therapy in NSCLC With Concomitant KRAS/TP53 Mutations

EP: 6.Molecular Testing in Advanced NSCLC: Recommended Targets and Methods

EP: 7.Optimizing Use of Molecular Testing in Advanced NSCLC

EP: 8.Overcoming Barriers to Molecular Testing in NSCLC

EP: 9.Immunotherapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements

EP: 10.Immunotherapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

Now Viewing

EP: 11.Immunotherapy in NSCLC With Concomitant KRAS/TP53 Mutations

EP: 12.Testing Strategies for Actionable Mutations in Non–Small Cell Lung Cancer

EP: 13.NSCLC: The Role of Liquid Biopsy in Molecular Testing and Treatment Decision-Making

EP: 14.Overcoming Barriers to Molecular Profiling in NSCLC Management

EP: 15.Is There a Role for PD-L1 Inhibitors in EGFR-Mutant or ALK-Rearranged NSCLC?

EP: 16.I/O Therapy in KRAS-Mutant NSCLC With Concomitant STK11 or KEAP1 Mutations

EP: 17.NSCLC: Immunotherapy in Patients With Concomitant KRAS/TP53 Mutations

Transcript:

Ticiana A. Leal, MD: Another interesting story has come out about immunotherapy in non–small cell lung cancer that has comutations with KRAS as well as TP53, and again, thinking about how this impacts the outcome for patients who are treated with PD-1 and PD-L1 inhibitors. Some of the evidence based on retrospective studies has shown that tumors with comutations with KRAS and TP53 may be susceptible to immunotherapy. We identify TP53 mutations when we do the NGS [next-generation sequencing] testing as well, and certainly, TP53 mutations are very common in non–small cell lung cancer. So, we identify TP53 mutations on the NGS reports.

I do think as we review our NGS reports, it’s very important to look at all the mutations, including TP53. Now again, we don’t have any significant or prospective data telling us, does this change what we do for patients with KRAS and comutations with TP53? But certainly, I think this is something to be aware of and to pay attention to as new data come in with future trials.

Transcript edited for clarity.